About Furiex Pharmaceuticals
Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company's product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Life Sciences Tools & Services
- Sub-Industry: Life Sciences Tools & Services
- Exchange: NASDAQ
- Symbol: FURX
- CUSIP: 36106P10
Companies Related to Furiex Pharmaceuticals:
- Previous Close: $0.00
- 50 Day Moving Average: $
- 200 Day Moving Average: $
- Trailing P/E Ratio:
- Foreward P/E Ratio: 99.78
- P/E Growth:
- Market Cap: $
Consensus Ratings for Furiex Pharmaceuticals (NASDAQ:FURX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Furiex Pharmaceuticals (NASDAQ:FURX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Furiex Pharmaceuticals (NASDAQ:FURX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/7/2014||Q114||($0.63)||($1.25)||$10.01 million||$6.40 million||View||N/A|
|3/11/2014||Q413||($1.06)||($0.63)||$12.80 million||$13.10 million||View||N/A|
|11/5/2013||Q313||($1.33)||($0.85)||$13.17 million||$15.55 million||View||N/A|
|8/6/2013||Q2 2013||($1.65)||($2.32)||$11.94 million||$3.00 million||View||N/A|
|5/7/2013||Q1 2013||$0.70||$0.82||$33.42 million||$39.33 million||View||N/A|
|3/6/2013||Q4 2012||($2.04)||($0.90)||$7.43 million||$9.21 billion||View||N/A|
Earnings Estimates for Furiex Pharmaceuticals (NASDAQ:FURX)
Current Year EPS Consensus Estimate: $-2.27 EPS
Next Year EPS Consensus Estimate: $1.05 EPS
Dividend History for Furiex Pharmaceuticals (NASDAQ:FURX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Furiex Pharmaceuticals (NASDAQ:FURX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/24/2014||Paul S Covington||VP||Sell||10,368||$104.12||$1,079,516.16|| |
|6/24/2014||Sailash Patel||CFO||Sell||32,928||$104.00||$3,424,512.00|| |
|6/18/2014||Paul S Covington||VP||Sell||45,691||$104.11||$4,756,890.01|| |
|6/17/2014||Gail Frances Mcintyre||SVP||Sell||74,457||$105.01||$7,818,729.57|| |
|6/13/2014||Paul S Covington||VP||Sell||3,228||$104.25||$336,519.00|| |
|6/10/2014||Gail Frances Mcintyre||SVP||Sell||1,746||$104.58||$182,596.68|| |
|6/10/2014||Paul S Covington||VP||Sell||2,872||$104.63||$300,497.36|| |
|6/10/2014||Sailash Patel||CFO||Sell||1,504||$104.68||$157,438.72|| |
|9/10/2013||Paul S Covington||VP||Sell||30,000||$40.89||$1,226,700.00|| |
|8/9/2013||Peter Corr||Director||Sell||7,500||$39.74||$298,050.00|| |
|7/19/2013||Gail Frances Mcintyre||SVP||Sell||10,581||$40.00||$423,240.00|| |
|3/12/2013||Stephen W Kaldor||Director||Sell||6,352||$41.58||$264,116.16|| |
|8/15/2012||June Sherie Almenoff||President||Buy||1,000||$18.67||$18,670.00|| |
Headlines for Furiex Pharmaceuticals (NASDAQ:FURX)
No headlines for this company have been tracked by MarketBeat.com
What is Furiex Pharmaceuticals' stock symbol?
Furiex Pharmaceuticals trades on the NASDAQ under the ticker symbol "FURX."
How do I buy Furiex Pharmaceuticals stock?
Shares of Furiex Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Furiex Pharmaceuticals stock cost?
One share of Furiex Pharmaceuticals stock can currently be purchased for approximately $104.77.
Furiex Pharmaceuticals (NASDAQ:FURX) Chart for Monday, February, 27, 2017
Institutional Ownership ChartEarnings History ChartDividend History Chart